Artelo Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>AB</div>
The stock continues to experience an active upward rally. ARTELO BIOSCIENCES Current Ratio is relatively stable at the moment as compared to the past year. The company's current value of Current Ratio is estimated at 4.96. Debt to Equity Ratio is expected to hike to 0.16 this year, although the value of Earnings before Tax will most likely fall to (4.3 M). While some millenniums are indifferent towards healthcare space, it makes sense to summarize ARTELO BIOSCIENCES INC as a unique investment alternative.
Published over two weeks ago
View all stories for Artelo Biosciences | View All Stories
Should I drop my ARTELO (NASDAQ:ARTL) holdings?
Debt to Equity Ratio is expected to hike to 0.16 this year. Average Equity is expected to hike to about 4.9 M this yearARTELO BIOSCIENCES holds a performance score of 20 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.1186, which signifies a somewhat significant risk relative to the market. Let's try to break down what ARTELO's beta means in this case. ARTELO BIOSCIENCES returns are very sensitive to returns on the market. As the market goes up or down, ARTELO BIOSCIENCES is expected to follow. Although it is essential to pay attention to ARTELO BIOSCIENCES INC historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy in foreseeing future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if ARTELO BIOSCIENCES INC expected return of 3.05 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use ARTELO BIOSCIENCES variance, value at risk, as well as the relationship between the Value At Risk and skewness to analyze future returns on ARTELO BIOSCIENCES.

How important is Artelo Biosciences's Liquidity

Artelo Biosciences financial leverage refers to using borrowed capital as a funding source to finance Artelo Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Artelo Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Artelo Biosciences's total debt and its cash.

How Artelo utilizes its cash?

To perform a cash flow analysis of Artelo Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Artelo Biosciences is receiving and how much cash it distributes out in a given period. The Artelo Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Artelo Biosciences Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (4.02 Million)

Detailed Perspective On Artelo Biosciences

The new price hike of ARTELO BIOSCIENCES INC could raise concerns from stakeholders as the firm it trading at a share price of 2.66 on very low momentum in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in March. The stock standard deviation of daily returns for 30 days investing horizon is currently 10.54. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the ARTELO BIOSCIENCES partners.

Asset Breakdown

Assets Non Current
1.8 M
2.9 M
Current Assets
Total Assets5.43 Million
Current Assets2.9 Million
Assets Non Current2.02 Million
Goodwill1.82 Million

Will ARTELO BIOSCIENCES growth be trustworthy after the hike?

Jensen alpha is down to 2.84. It may denote a possible volatility pull down. ARTELO BIOSCIENCES INC is displaying above-average volatility over the selected time horizon. Investors should scrutinize ARTELO BIOSCIENCES INC independently to ensure intended market timing strategies are aligned with expectations about ARTELO BIOSCIENCES volatility.

While some other entities under the biotechnology industry are still a bit expensive, ARTELO BIOSCIENCES may offer a potential longer-term growth to stakeholders. With a relatively neutral outlook on the new economy, it is better to hold off any trading of ARTELO as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ARTELO BIOSCIENCES.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Artelo Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to